| 连花清瘟治疗新型冠状病毒肺炎的理论研究基础和临床疗效 |
| |
| 引用本文： | 李红蓉,常丽萍,魏聪,贾振华.连花清瘟治疗新型冠状病毒肺炎的理论研究基础和临床疗效[J].世界中医药,2020,15(3):332-336. |
| |
| 作者姓名： | 李红蓉 常丽萍 魏聪 贾振华 |
| |
| 作者单位： | 河北以岭医院,石家庄,050091;络病研究与创新中药国家重点实验室,石家庄,050035;国家中医药管理局重点研究室(心脑血管络病),石家庄,050035;河北以岭医院,石家庄,050091;国家中医药管理局重点研究室(心脑血管络病),石家庄,050035;河北以岭健康管理中心,石家庄,050035;河北以岭医院,石家庄,050091;络病研究与创新中药国家重点实验室,石家庄,050035;河北以岭健康管理中心,石家庄,050035;河北以岭医院,石家庄,050091;络病研究与创新中药国家重点实验室,石家庄,050035;河北以岭医药研究院,石家庄,050035 |
| |
| 基金项目： | 北京市科学技术委员会新冠病毒肺炎应急项目；河北省科技厅新冠病毒肺炎防控应急科研攻关专项（20277708D） |
| |
| 摘 要： | 新型冠状病毒肺炎以免疫系统功能紊乱及炎性反应引起深部气道和肺泡损伤为特征性病理表现,还可见较重的肺瘀血表现,属中医肺络病变范畴。连花清瘟胶囊(颗粒)是以络病理论为指导研制的呼吸系统传染病代表性治疗药物,对SARS-CoV、MERS-CoV等多种病毒和炎性反应具有抑制作用。其理论组方特色和基础临床研究得到了广泛认可,被纳入国家和多个地区的新型冠状病毒诊疗方案。最新的研究结果表明连花清瘟可以体外抑制新型冠状病毒活性,并显著改善新型冠状病毒肺炎患者的发热、咳嗽、乏力等症状,为应用连花清瘟治疗新型冠状病毒肺炎提供了理论和临床依据。
|
| 关 键 词： | 新型冠状病毒肺炎 连花清瘟 络病理论 肺络病变 炎症风暴 |
| 收稿时间： | 2020/2/28 0:00:00 |
Theoretical Research Basis and Clinical Efficacy of Lianhua Qingwen in Treating Novel Coronavious Pneumonica |
| |
| LI Hongrong,CHANG Liping,WEI Cong,JIA Zhenhu.Theoretical Research Basis and Clinical Efficacy of Lianhua Qingwen in Treating Novel Coronavious Pneumonica[J].World Chinese Medicine,2020,15(3):332-336. |
| |
| Authors: | LI Hongrong CHANG Liping WEI Cong JIA Zhenhu |
| |
| Institution: | 1 Hebei Yiling Hospital,Shijiazhuang 050091,China; 2National Key Laboratory of Luobing Research and Innovative Chinese Medicine,Shijiazhuang 050035,China; 3 Key Laboratory Cardio-cerebral Vessel Collateral Disease,State Administration of Traditional Chinese Medicine,Shijiazhuang 050035,China; 4 Hebei Yiling Health Management Center,Shijiazhuang 050035,China; 5 Hebei Yiling Pharmaceutical Research Institute,Shijiazhuang 050035,China |
| |
| Abstract: | The novel coronavious pneumonica(NCP)is considered as lung collateral disease in TCM,which is characterized by the dysfunction of immune system and the damage of deep airway and alveoli caused by inflammatory reaction,and also characterized by severe pulmonary congestion.Lianhua Qingwen is a representative treatment drug for respiratory diseases,which is guided by“Collateral Disease”theory.It has inhibitory effects on many viruses like SARS-CoV,MERS-CoV and inflammatory reactions.It has been incorporated into national and regional diagnosis and treatment programs of COVID-19,as its theoretical formulation features and basic clinical research have been widely recognized.The latest research showed that Lianhua Qingwen can inhibit activity of COVID-19 in vitro,and alleviate fever,cough,fatigue and other symptoms of NCP patients significantly.All of these have provided theoretical and research basis for the treatment of NCP with Lianhua Qingwen. |
| |
| Keywords: | Coronavirus Disease 2019 Lianhua Qingwen “Collateral Disease”theory lung collateral disease Inflammation storm |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《世界中医药》浏览原始摘要信息 |
| 点击此处可从《世界中医药》下载免费的PDF全文 |
|
